The Heart of the Disagreement
On the surface, a trade deal seems like a clear win-win. For India, it offers the potential for lower tariffs and more reliable access to its largest export market, the United States. For the US, it’s a chance to sell more goods and services to one of the world's
fastest-growing economies. However, the negotiations have hit a wall, with officials on both sides acknowledging a 'plateau' in talks. The core of the stalemate lies not in minor details but in major philosophical differences, primarily centred on intellectual property (IP) rights for pharmaceuticals and pricing controls on medical devices.
The Intellectual Property Impasse
The US is a global leader in pharmaceutical research and development, and its trade policy fiercely protects the patents and clinical trial data of its corporations. Washington has been pushing for India to adopt stronger IP protections. This includes a measure known as 'data exclusivity,' which would prevent Indian generic drug manufacturers from using the clinical trial data of foreign pharmaceutical companies to get swift approval for their own, more affordable versions of medicines. For the US, this is about rewarding innovation and protecting massive R&D investments. For India, often called the 'pharmacy of the world,' this is a direct challenge to a business model that has made life-saving drugs affordable for millions globally. India's government has resisted these changes, prioritizing its commitment to public health and the accessibility of medicines over the commercial interests of multinational pharmaceutical giants.
The Medical Device Dilemma
A second major sticking point is India's pricing policy for medical devices. To make critical healthcare more affordable, India's National Pharmaceutical Pricing Authority (NPPA) has imposed price caps on essential devices like coronary stents and knee implants. In some cases, these caps reduced prices by as much as 80%. From India's perspective, this is a sovereign policy decision aimed at ensuring patient welfare. However, US manufacturers, who are major suppliers of high-end medical devices to the Indian market, view these price controls as a significant trade barrier. They argue that the caps are imposed without regard for the quality or technological sophistication of the device, unfairly disadvantaging their advanced products and hurting profitability. The US has consistently demanded the removal of these price caps as a condition for the trade deal.
Stakes Beyond a 'Mini-Deal'
While initially envisioned as a 'mini-deal' or an interim agreement, the talks have revealed just how far apart the two nations are on core economic principles. The US seeks greater market access for its companies, arguing for a level playing field based on free-market principles. India, while open to trade, remains protective of its domestic industries and its policy space to regulate in the interest of public health and affordability. This fundamental tension is why a deal that seems 'pretty close' on paper has remained elusive in practice. Recent high-level visits and statements from officials on both sides express optimism, but the underlying conflicts persist, leaving the future of the trade pact uncertain despite ongoing negotiations.
